Another Chance for Collaboration With ACTG on HIV Remission and Cure

Funding News Edition: February 02, 2022
See more articles in this edition

The AIDS Clinical Trials Group (ACTG) is an NIAID-supported network conducting research to improve the treatment of HIV and its co-infections and advance approaches to ultimately cure HIV. ACTG, in partnership with NIAID’s Division of AIDS, recently announced an opportunity for collaboration and funding of Small Clinical Trials Advancing HIV Remission and Cure.

Consider applying if you have an idea that will help identify a new strategy to address HIV remission and cure. Your proposed trial should be small, with less than 30 participants, and can include specialized assays and procedures. The opportunity allows you to leverage ACTG infrastructure to explore your idea.

Applications are due on April 1, 2022. If you plan to apply, send an optional letter of intent by February 15. A second application due date follows on September 1, 2022, for which optional letters of intent are due July 1.

Keep in mind, this is not an NIH funding opportunity announcement, so while you may consider general advice about applying for a grant from our website, ultimately you must follow ACTG’s policies and procedures. Be sure to read the Frequently Asked Questions document as well. ACTG will evaluate proposals for merit, with the budget developed and finalized after the concepts are approved.

Direct any inquiries to

Contact Us

Email us at for help navigating NIAID’s grant and contract policies and procedures.

Content last reviewed on